Quoin Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Quoin Pharmaceuticals has a total shareholder equity of $5.7M and total debt of $3.5M, which brings its debt-to-equity ratio to 62.2%. Its total assets and total liabilities are $12.2M and $6.5M respectively.
Key information
62.2%
Debt to equity ratio
US$3.52m
Debt
| Interest coverage ratio | n/a |
| Cash | US$10.69m |
| Equity | US$5.66m |
| Total liabilities | US$6.51m |
| Total assets | US$12.17m |
Financial Position Analysis
Short Term Liabilities: QNRX's short term assets ($11.3M) exceed its short term liabilities ($3.6M).
Long Term Liabilities: QNRX's short term assets ($11.3M) exceed its long term liabilities ($2.9M).
Debt to Equity History and Analysis
Debt Level: QNRX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if QNRX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: QNRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: QNRX has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 39.1% each year.